Literature DB >> 3717517

Methotrexate as relapse therapy for rhabdomyosarcoma.

U Bode.   

Abstract

Four patients had a local relapse after standard therapy for rhabdomyosarcoma and were treated with high-dose 42-hour MTX infusions. All patients responded to this therapy, one patient had a complete, and two patients a partial remission. Long duration MTX infusion should be part of a combination chemotherapy for relapsed rhabdomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717517

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  2 in total

1.  Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.

Authors:  F M Balis; A Gillespie; J Belasco; G H Reaman; L J Ettinger; R F Murphy; K Doherty; S Jeffries; M E Horowitz; D G Poplack
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.

Authors:  J D Borsi; D Schuler; P J Moe
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.